Skip to content

Clinical research to evaluate efficacy of KMY2 as a supplement

Clinical research to evaluate efficacy of KMY2 as a supplement

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080223721
Enrollment
80
Registered
2017-11-16
Start date
2017-11-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

investigational material(s) Generic name etc : KMY2 INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : 1capsule / day co

Sponsors

ROHTO Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)From 6 to 12 years old 2)Myopia (from -1.50D to -4.50D) 3)Astigmatism (1.5D or under) 4)Not having any eye disease except for refractive error 5)Already wearing glasses for myopia 6)More than one of his/her parens are myopia 7)Obeying given instructions 8)Being able to use glasses prescribed in this study 9)Agreeing to join this study

Exclusion criteria

Exclusion criteria: 1)Parallax (over 1.5D) 2)Astigmatism (over 1.50D) 3)Corrected visual acuity with single eye is lower than 1.0 4)Strabismus 5)Nallow-angle 6)Wearing contact lenses 7)Having allergy to ingredients or reagents used in this study 8)Participating in other similar studies 9)Taking medicines or supplements that could bring influence to this study 10)Having any treatment history for the same purpose as this study 11)Other conditions that is supposed not proper for this study

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026